本文核心数据：脑机接口领域细分市场情况;脑机接口领域侵入式脑机接口分析 1、中国脑机接口行业细分市场情况 脑机接口按照信号采集方式可以通常分为侵入式、半侵入式和非侵入式三大类别。目前侵入式脑机接口 的研究主要集中在开发新型材料以及更精细的电极以提高生物相容性，非侵入式产品研究主要集中在改 进材料以提升电极导电率、改进结构以促进电极与皮肤充分接触。较多公司侧重开发非侵入式产品，涉 及教育和泛娱乐、健康和睡眠辅助等。在侵入式领域内深耕的国内公司为数不多，少量公司正在开发无 创或微创的产品与解决方案，以用来进行脑科学研究、精神与心理疾病筛查，各类神经系统疾病监护、 诊疗与康复。 转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院脑机接口研究小组发布的《全球及中国脑机接口（BCI）行业发 展前景展望与投资机遇分析报告》。 行业主要上市公司：翔宇医疗(688626)、岩山科技(002195)、科大讯飞(002230)、伟思医疗(688580)、爱 朋医疗(300753)、三博脑科(301293)、创新医疗(002173)等 2、侵入式脑机接口分辨率高 侵入式脑机接口指通过神经外科手术将电极等信号记录装置植入脑内特 ...

Company Overview - Brain-computer interface company, BoRuiKang Technology (Shanghai) Co., Ltd., has completed its IPO counseling registration on February 4, 2026, with CITIC Securities as the counseling broker, marking the official start of its Sci-Tech Innovation Board IPO process [1][2][3] - Established in November 2011, BoRuiKang's core team includes experts from Tsinghua University's Neural Engineering Laboratory and clinical neuroscience, focusing on the research, production, and technical services of brain-computer interface systems [3][4] - The company has developed products for clinical diagnosis and research education, including digital EEG machines and transcranial electrical stimulation systems, with some products already receiving medical device registration [3][4] Product Development - BoRuiKang's flagship product, the NEO wireless minimally invasive brain-computer interface system, is the world's first to use an epidural implant with fully wireless transmission design [3][4] - NEO employs a "semi-invasive" technique, implanting coin-sized electrodes beneath the skull but outside the dura mater, allowing proximity to neurons without direct contact, thus avoiding damage to neural tissue [4] - The NEO system has undergone successful clinical trials, with 32 patients having completed implantation across 11 hospitals, achieving a 100% success rate in primary clinical endpoints [4][5] Regulatory Progress - NEO is set to submit a Class III innovative medical device registration application to the National Medical Products Administration, potentially becoming the first marketed implantable brain-computer interface product in China [5] - The product's first version, NEO 1.0, is expected to be followed by a 2.0 version that will include additional features such as language decoding and small limb decoding [5] Financial Backing and Valuation - BoRuiKang has completed multiple rounds of financing, with notable investors including Sequoia China and Baidu Ventures, achieving a post-investment valuation of 3.5 to 4 billion yuan by the end of 2025 [5][6] - The company has raised a total of 1.2 million yuan in angel funding and 30 million yuan in Pre-A funding, among other financing rounds [5] Industry Context - The brain-computer interface industry is experiencing significant growth opportunities in China, supported by favorable policies and market conditions [9][10] - The Ministry of Industry and Information Technology and other departments have included brain-computer interfaces in key future industry cultivation, with projections indicating the market could exceed 120 billion yuan by 2040 [10]

Core Viewpoint - Zhejiang Qiangnao Technology Co., Ltd. has reportedly submitted a confidential IPO application to the Hong Kong Stock Exchange, with CICC and UBS as joint sponsors, indicating a significant move towards public listing in the rapidly growing brain-computer interface (BCI) sector [1][3]. Company Overview - Founded in February 2015, Qiangnao Technology focuses on the development of non-invasive brain-computer interface technology, with products spanning smart bionics, health, and education [1]. - The company has launched several products, including a smart bionic hand, a brain-machine intelligent sleep device, and an attention training system [1]. Financing History - Qiangnao Technology completed a significant financing round in early January, raising approximately 2 billion RMB, marking it as the second-largest financing in the BCI field globally, after Neuralink [3]. - Since its inception, the company has completed six rounds of financing, including a notable $400 million Series A round in 2019 [3][4]. - The latest financing rounds include a $30 million Pre-B round and a $20 million Series B round in 2025 [4]. Market Trends - The BCI sector is experiencing rapid growth, with 26 financing events in 2025 totaling 1.778 billion RMB, a significant increase from 2024 [5]. - The global BCI market is projected to grow from approximately $2.6 billion in 2024 to $2.9 billion in 2025, with a further increase to $3.3 billion by 2026 [5]. - In China, the BCI market is expected to reach 3.8 billion RMB in 2025, up from 3.2 billion RMB in 2024 [5]. Policy Support - The Chinese government is actively promoting the BCI industry, with policies aimed at fostering innovation and establishing industry clusters by 2027 and 2030 [7]. - The national strategy includes BCI as a key area for economic growth, alongside other advanced technologies [7]. Industry Outlook - Analysts predict that the BCI industry is on the verge of significant growth, driven by commercial advancements and policy support [8]. - The transition from laboratory research to commercialization is expected to accelerate, particularly with the anticipated production scale-up by Neuralink [8].

Core Viewpoint - The article discusses the significant financing of 2 billion RMB for BrainCo, positioning it as a leading player in the non-invasive brain-computer interface (BCI) sector, contrasting it with Neuralink's invasive approach, highlighting the ongoing technological rivalry in the BCI industry [5][18]. Financing and Growth - BrainCo completed a financing round of approximately 2 billion RMB, led by IDG and Huaden International, making it the second-largest BCI company in terms of funding globally, after Neuralink [5][18]. - Since 2019, BrainCo has completed four financing rounds, accumulating a total of 4.684 billion RMB [15]. Technology Pathways - BrainCo focuses on non-invasive BCI technology, utilizing devices like EEG caps to collect signals, which offers safety and ease of acceptance, while facing challenges in signal precision [6][12]. - Neuralink represents the invasive BCI route, which involves surgical implantation of electrode arrays in the brain, allowing for high-resolution signal collection but poses risks and ethical concerns [5][12]. Product Development and Market Position - BrainCo has developed several products, including smart prosthetics and sleep regulation devices, with some receiving FDA and CE certifications for international sales [6][14]. - The company achieved a milestone in 2022 by producing 100,000 units of a portable high-precision BCI product, breaking the long-standing experimental phase in the industry [14]. Competitive Landscape - The BCI market is characterized by three main technological pathways: invasive, semi-invasive, and non-invasive, each balancing performance, safety, and accessibility differently [20][22]. - Non-invasive BCIs, led by companies like BrainCo, dominate the market, accounting for approximately 82% of the BCI market share, while invasive technologies hold about 18% [22].

Core Viewpoint - The announcement by Elon Musk regarding Neuralink's plans for large-scale production of brain-machine interface (BMI) devices by 2026 has ignited significant interest in the capital markets, indicating a shift from experimental to industrial-scale applications of this technology [3][5]. Industry Developments - Brain-machine interfaces (BMIs) are categorized into three types: invasive, semi-invasive, and non-invasive, each with varying levels of signal quality and risk [4]. - Neuralink has achieved rapid advancements, including a 1.5-second implantation process and successful trials on both animals and humans, with seven patients receiving implants as of mid-2025 [4][5]. - The Chinese government has shown support for the BMI industry, with policies and plans aimed at fostering innovation and development in this field [8][10]. Market Reaction - Following Musk's announcement, the A-share market saw a surge in BMI-related stocks, with significant gains observed in various companies within this sector [6]. - Strong Brain Technology, a company focused on non-invasive BMI technology, secured approximately 2 billion yuan in funding, highlighting investor confidence in the BMI market [6]. Future Outlook - Experts predict that 2026 could be a pivotal year for BMIs, marking the transition of this technology from laboratory settings to commercial viability [7][10]. - The advancements in BMI technology are expected to lead to a broader range of applications in the medical field, moving from experimental tools to widely available products [10].

Core Viewpoint - The article highlights the advancements in brain-computer interface technology through the example of Qiangnao Technology, which has developed a smart bionic hand that enables users to perform complex tasks, showcasing the potential for human-robot coexistence in the future [1][3]. Group 1: Company Overview - Qiangnao Technology, founded in 2015, is the first unicorn in the brain-computer interface sector in China, focusing on non-invasive brain-computer interface technology for nearly a decade [5]. - The company recently completed a financing round of approximately 2 billion yuan, making it the second-largest in the global brain-computer interface field after Neuralink [3]. Group 2: Product Development - Qiangnao Technology has launched several products, including smart bionic hands and legs, as well as brain-machine intelligent sleep devices, creating a product matrix that spans medical rehabilitation, consumer health, and advanced robotics [8]. - The smart bionic hand has been successfully used in major events such as the Beijing Winter Paralympics and the Hangzhou Asian Para Games, indicating its practical application and recognition [10]. Group 3: Technological Advancements - The company has developed a solid gel electrode that allows for convenient brain signal acquisition without the need for conductive paste, overcoming a significant barrier in non-invasive technology [7]. - Qiangnao's Revo 2 bionic hand, weighing only 383 grams, can exert a grip force of 50N and carry weights of up to 20kg, showcasing its advanced multi-modal tactile sensing capabilities [12]. Group 4: Competitive Advantage - Qiangnao Technology has established a unique technological and commercial moat through large-scale production and cost control, managing to reduce the cost of its smart bionic hand to one-fifth to one-seventh of similar products in Europe and the U.S. [15]. - The company has achieved mass production of 100,000 units of high-precision brain-computer interface products, demonstrating its capability for industrial-scale production [15]. Group 5: Future Vision - With the recent funding, Qiangnao Technology aims to accelerate technological iterations, expand into global markets, and deepen its product offerings in rehabilitation, health, and human-machine interaction [16]. - The company's strategic direction is evolving from addressing rigid medical needs to broader applications in health, targeting to assist 1 million individuals with physical disabilities and 10 million patients with Alzheimer's, autism, and sleep disorders within the next 5 to 10 years [18].

Group 1 - The core viewpoint of the news is that Qiangnao Technology, a brain-computer interface company, has completed a financing round of approximately 2 billion yuan, marking the second-largest financing record in the brain-computer interface field globally, after Neuralink [1] - The funds raised will be used to accelerate the research and development of core technologies, extreme engineering breakthroughs, and the mass production of products [1] - The investor lineup for this financing includes prominent institutions such as IDG, Huaden International founded by Intel CEO Chen Liwu, and major companies like Lens Technology and Lingyi Technology [1] Group 2 - Qiangnao Technology aims to help 1 million disabled individuals regain daily life through neural-controlled prosthetics and improve the conditions of 10 million patients suffering from brain diseases like autism and Alzheimer's within the next five to ten years [2] - The company, founded in February 2015, focuses on non-invasive brain-computer interface technology and has achieved significant milestones, including FDA and CE certifications [2] - The industry landscape shows that Neuralink remains the highest-valued company in the brain-computer interface sector, with a valuation of 9 billion USD expected after its Series E financing in 2025 [2] Group 3 - According to a recent report from Kaisheng Securities, the brain-computer interface technology is expected to commercialize by 2026, transitioning from medical necessities to AI applications [3] - Qiangnao Technology has significant potential for expansion in overseas markets, as highlighted by its founder's participation in the China-Korea Innovation and Entrepreneurship Forum [3] - With increased investment in brain science and the launch of the "Brain Plan" in China, the sector is entering a new phase of technological realization and commercial explosion [3]

Core Viewpoint - BrainCo, a leading company in the brain-computer interface (BCI) sector, has successfully completed a financing round of approximately 2 billion RMB, marking it as the second-largest financing in the global BCI market, following Neuralink [2] Financing and Investment - The recent financing attracted a prestigious lineup of investors, including IDG, Huaden International, and major industry players like Lens Technology and Lingyi iTech [2] - BrainCo's financing history shows a consistent increase in capital recognition, with significant rounds including 400 million USD in Series A in 2019 and 30 million USD in Pre-B and 20 million USD in Series B in 2025 [3] - The company is preparing for an IPO, potentially in Hong Kong or mainland China, with a valuation exceeding 1.3 billion USD anticipated for the upcoming round [3] Company Background and Product Development - Founded in February 2015 by Han Bicheng, BrainCo focuses on non-invasive BCI technology, having developed products like smart prosthetics and sleep improvement devices [3][4] - The company has received FDA and CE certifications, making it one of the few globally to achieve large-scale production of BCI products [4] Future Plans and Market Potential - BrainCo aims to assist 1 million individuals with physical disabilities and 10 million patients suffering from Alzheimer's, autism, and insomnia over the next 5 to 10 years [5] - The company is committed to advancing non-invasive BCI solutions for mental health issues like depression and Alzheimer's, aligning with China's increased investment in brain science [5] Industry Landscape - Neuralink remains the highest-valued BCI company globally, with a valuation of 9 billion USD post-E round financing in 2025 [5] - The BCI sector is gaining traction in the capital market, with several A-share companies experiencing significant stock performance related to BCI concepts [6] - Companies like Aihuilong and Kefu Medical are entering the BCI space, indicating a growing interest and investment in this emerging field [6] Investment Opportunities - The BCI industry is in its early commercialization phase, with a focus on thematic investment strategies [6] - There is potential for significant revenue generation in non-invasive BCI products, as well as opportunities in software, hardware, and experimental materials related to BCI [6]

Core Insights - Strong Brain Technology, led by Han Bicheng, has secured approximately 2 billion yuan in funding, marking the largest financing in China's brain-computer interface sector [2] - This funding round positions Strong Brain Technology as the second largest globally in the brain-computer interface space, following Neuralink's 650 million USD Series E funding [2] Company Overview - Han Bicheng, the founder of Strong Brain Technology, is a 39-year-old from Mudanjiang, Heilongjiang, with a distinguished academic background, including a bachelor's degree in mechanical engineering from the Korea Advanced Institute of Science and Technology and a PhD from Harvard University [3][4] - The company was established in 2015, and Han chose to return to China to start the business before completing his PhD [5] Technology and Product Development - Strong Brain Technology focuses on non-invasive brain-computer interface technology, which is considered a "non-mainstream" approach compared to the invasive methods predominantly supported by investors [6][8] - The company has developed a "super sensor" capable of detecting neural signals, achieving over 95% accuracy in signal recognition compared to medical-grade EEG devices [8] - Products include smart bionic limbs and brain-computer intelligent sleep devices, with a production milestone of 100,000 high-precision brain-computer interface products reached in 2022 [8] Market Position and Future Goals - The market price for the smart bionic hand is approximately 100,000 yuan, significantly lower than similar foreign products, and allows for immediate use after installation [10] - Strong Brain Technology aims to assist over 6,000 disabled individuals in regaining mobility by 2025, with a long-term vision of helping 1 million individuals with limb disabilities and 10 million patients with Alzheimer's, autism, and insomnia over the next 5 to 10 years [10][12] - The company's valuation reached 9 billion yuan in the 2025 Hurun Global Unicorn List, reflecting its growth and potential in the industry [12]

Core Insights - Elon Musk has provided a timeline for mass production of brain-computer interface (BCI) devices, igniting interest in global capital markets, with related indices in A-shares rising over 13% on the first trading day of the year [1] - Strong Brain Technology recently completed a significant financing round of approximately 2 billion RMB, marking the second-largest financing in the global BCI sector after Neuralink [1] - The Chinese government has included BCI technology in its "14th Five-Year Plan," indicating a strong push towards commercialization and innovation in the industry [1][3] Company Overview - Strong Brain Technology was founded in February 2015 and has developed non-invasive BCI technologies, including smart bionic limbs and sleep aids, achieving FDA and CE certifications [2] - The company has a history of substantial financing, including a $400 million Series A round in 2019, and plans for an IPO in Hong Kong or mainland China with a valuation exceeding $1.3 billion [2] Market Dynamics - The Chinese BCI market is projected to exceed 3.8 billion RMB by 2025, with medical health applications accounting for 56%, and is expected to surpass 10 billion RMB by 2030 [3] - The government plans to invest over 50 billion RMB in the BCI industry during the "14th Five-Year Plan," aiming to cultivate 2-3 global leading companies by 2030 [3] Future Development - Strong Brain Technology aims to accelerate research and development in rehabilitation and consumer sectors, with a vision to assist 1 million individuals with physical disabilities and 10 million patients suffering from brain-related conditions over the next 5 to 10 years [4] - The company emphasizes the importance of making BCI technology accessible to the general public, aligning with the "technology for good" philosophy [4] Global Industry Landscape - Neuralink remains the highest-valued BCI company globally, with a valuation of $9 billion following its Series E funding round in 2025 [5] - The BCI technology is expected to achieve commercialization by 2026, with applications expanding from medical needs to AI and robotics [5] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, indicating significant investment potential in both medical and technological sectors [5]